Standigm is an AI-driven workflow drug discovery company that aims to improve the success rates and efficiency of new drug development.
Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 30, 2021 | Series D | $10M | 1 | Pavilion Capital | — | Detail |
Mar 5, 2021 | Series C | $36.41M | 2 | SKS PE | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Pavilion Capital | Yes | Series D |
SKS PE | Yes | Series C |
Asset One | — | Series C |